Compare Merck & Co., Inc. (MRK) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Quanta Services Inc — how do they compare? Merck & Co., Inc. trades at $125.97 (market cap $307.25B), while Quanta Services Inc trades at $640.05 (market cap $94.92B). The key difference: Merck & Co., Inc. is far larger — about 3.2× Quanta Services Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | PWR | |
|---|---|---|
Market Cap | $307.25B | $94.92B |
Sector | Health | Industrials |
52-Week High | $129.52 | $785.24 |
52-Week Low | $77.60 | $372.50 |
Enterprise Value | $350.66B | $100.88B |
Dividend Yield | 2.73% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
PWR (Quanta Services) trades at $639.20, up 1.7% with strong analyst support (75% buy ratings) and a consensus price target of $836.80. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 3.67%. Recent technical indicators are bearish despite oversold RSI readings, with key support at $613. The company benefits from AI infrastructure demand and utility spending, with a record $48B backlog.
Outlook is positive given exposure to grid modernization and AI data center build-out, but high valuation (P/E 86.77) and execution risks pose challenges. Earnings have consistently beaten estimates, with Q2 2026 results due July 30. Institutional sentiment is bullish, though technical weakness near-term warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
